US drugmaker Eli Lilly and Company announced that it was slashing prices of its most commonly-prescribed insulins by 70 percent. Lilly said it would cut the price of its non-branded insulin to $25 a vial from May 1. It will also cut the price of Humalog, the company’s most commonly-prescribed insulin and Humalin injections by 70 percent towards the end of the year.
